What is VIDAZA (Azacitidine)?
VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
What is the most important information I should know about VIDAZA?
- Advise women of childbearing potential to avoid becoming pregnant while receiving treatment with VIDAZA. For nursing mothers, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into consideration the importance of the drug to the mother.
-
Advise men not to father a child while receiving treatment with VIDAZA
VIDAZA can cause serious side effects. These serious side effects include:
- Anemia
- Neutropenia
- Thrombocytopenia
- Elevated serum creatinine
- Renal failure
- Renal tubular acidosis
- Hypokalemia
- Hepatic coma
What are the common side effects of VIDAZA?
- Nausea
- Thrombocytopenia
- Pyrexia
- Diarrhea
- Constipation
- Ecchymosis
- Rigors
- Anemia
- Vomiting
- leukopenia
- Injection site erythema
- Neutropenia
- Petechiae
- Weakness
Important Safety Information
- Patients to inform their physician about any underlying liver or renal disease.
- Women of childbearing potential to avoid becoming pregnant while receiving treatment with VIDAZA. For nursing mothers, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into consideration the importance of the drug to the mother.
- Men not to father a child while receiving treatment with VIDAZA
What should I tell my healthcare provider before taking VIDAZA?
ITell your healthcare provider about all the medicines you take.